Monday, 22 Jan 2018

You are here

Cardiac Disturbances Increased in Spondyloarthritis

A prospective nationwide study from Sweden analyzed patients with AS (n=6448), PsA (n=16 063),  undifferentiated spondyloarthritis (uSpA; n=5190) and a general population controls (GP; n=2 66 435) between 2001–2009 and found a higher risk of aortic regurgitation and pacemaker use in SpA and higher risk of AV block, especially in men with AS or uSpA.

Atrial fibrillation (AF) wsa most common cardiac abnormality (5.5–7.4 events per 1000 person-years), followed by pacemaker implantation (PM) (1.0–2.0 events per 1000 person-years).

AS patients had significantly  increased hazard rations (HR) for AV block (HR 2.3), AF (1.2), PM (2.1) and aortic regurgitation (1.9). Higher  rates of all of these were seen in uSpA (HRs 2.9, 1.3, 1.9 and 2.0, respectively) and PsA (HRs 1.5, 1.5, 1.6 and 1.8, respectively) compared to controls.

The highest HRs were seen for AV block in male uSpA (HR 4.2) and AS (HR 2.5) compared with GP.

Pacemakers were higher in AS (HR 1.5) and AV blodk was also higher in uSpA (HR 1.5) when compared to PsA patients.

Conduction and valvular dysfunction is more common amongst SpA patients and should be screened for, especially in men.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

FDA Approves Xeljanz for Use in Psoriatic Arthritis

Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has approved Xeljanz (tofacitinibi) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

2017 Update of Treat to Target Recommendations for SpA/PsA

A 2017 international committee of experts met to assess and revise its earlier 2012 recommendations regarding treating to target in patients with psoriatic arthritis (PsA) and axial peripheral spondyloarthritis (SpA).